Abbott Offers EU Antitrust Remedies On Solvay Deal
The European Commission extended its deadline to review Abbott Laboratories' $6.6 billion bid for Solvay Group's pharmaceutical business on Friday, after Abbott offered remedies to the antitrust watchdog's concerns over a...To view the full article, register now.
Already a subscriber? Click here to view full article